Publicaciones en colaboración con investigadores/as de Princess Margaret Hospital (9)

2023

  1. Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

2009

  1. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

    Blood, Vol. 114, Núm. 6, pp. 1166-1173

  2. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2007

  1. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

    Blood, Vol. 110, Núm. 10, pp. 3557-3560

2005

  1. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498

2004

  1. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report

    Cancer Research